(169) Assay Card

General Information
Summary Inhibitory activity of cMCoTI-fxL1 against a panel of serine proteases
Condition Refer "Protease inhibition assays" described in the method part (Liu et al., 2021).
Result FxIIa: Ki=0.69+/-0.04 nM; Trypsin: Ki=996+/-17 nM; FXa: IC50>5uM(0%); FXIa: IC50>5uM(1%); Thrombin: IC50>5uM(1%); Plasma kallikrein: IC50>5uM(0%); Plasmin: IC50>5uM(19%); uPA: IC50>5uM(0%); tPA: IC50>5uM(1%); Matriptase: Ki=2210+/-130 nM.
AssayType Protease inhibition

References
Liu W, de Veer SJ, Huang YH, Sengoku T, Okada C, Ogata K, Zdenek CN, Fry BG, Swedberg JE, Passioura T, Craik DJ, Suga H. (2021) An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human beta-Factor XIIa in a Cyclotide Scaffold J Am Chem Soc 143:18481-18489

Cross-references
Proteins Assayed cMCoTI-fxL1